Cross Country Healthcare, Inc.

NasdaqGS:CCRN Stock Report

Market Cap: US$341.3m

Cross Country Healthcare Future Growth

Future criteria checks 3/6

Cross Country Healthcare's revenue is forecast to decline at 5.3% per annum while its annual earnings are expected to grow at 119.4% per year. EPS is expected to grow by 113.3% per annum. Return on equity is forecast to be 4.2% in 3 years.

Key information

119.4%

Earnings growth rate

113.3%

EPS growth rate

Healthcare earnings growth20.8%
Revenue growth rate-5.3%
Future return on equity4.2%
Analyst coverage

Good

Last updated12 Nov 2024

Recent future growth updates

Recent updates

Cross Country Healthcare: The Strong Balance Sheet Provides A Sufficient Margin Of Safety

Oct 15

Cross Country Healthcare, Inc.'s (NASDAQ:CCRN) Shares Bounce 30% But Its Business Still Trails The Market

Jul 31
Cross Country Healthcare, Inc.'s (NASDAQ:CCRN) Shares Bounce 30% But Its Business Still Trails The Market

Benign Growth For Cross Country Healthcare, Inc. (NASDAQ:CCRN) Underpins Stock's 25% Plummet

Feb 22
Benign Growth For Cross Country Healthcare, Inc. (NASDAQ:CCRN) Underpins Stock's 25% Plummet

Calculating The Intrinsic Value Of Cross Country Healthcare, Inc. (NASDAQ:CCRN)

Feb 09
Calculating The Intrinsic Value Of Cross Country Healthcare, Inc. (NASDAQ:CCRN)

Cross Country Healthcare (NASDAQ:CCRN) Is Achieving High Returns On Its Capital

Oct 09
Cross Country Healthcare (NASDAQ:CCRN) Is Achieving High Returns On Its Capital

Should You Investigate Cross Country Healthcare, Inc. (NASDAQ:CCRN) At US$23.23?

Sep 13
Should You Investigate Cross Country Healthcare, Inc. (NASDAQ:CCRN) At US$23.23?

These 4 Measures Indicate That Cross Country Healthcare (NASDAQ:CCRN) Is Using Debt Reasonably Well

Aug 19
These 4 Measures Indicate That Cross Country Healthcare (NASDAQ:CCRN) Is Using Debt Reasonably Well

Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

Jun 26
Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

At US$27.39, Is It Time To Put Cross Country Healthcare, Inc. (NASDAQ:CCRN) On Your Watch List?

Jun 08
At US$27.39, Is It Time To Put Cross Country Healthcare, Inc. (NASDAQ:CCRN) On Your Watch List?

Is Cross Country Healthcare (NASDAQ:CCRN) Using Too Much Debt?

Apr 28
Is Cross Country Healthcare (NASDAQ:CCRN) Using Too Much Debt?

Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

Mar 15
Returns on Capital Paint A Bright Future For Cross Country Healthcare (NASDAQ:CCRN)

Why Cross Country Healthcare, Inc. (NASDAQ:CCRN) Could Be Worth Watching

Mar 02
Why Cross Country Healthcare, Inc. (NASDAQ:CCRN) Could Be Worth Watching

If EPS Growth Is Important To You, Cross Country Healthcare (NASDAQ:CCRN) Presents An Opportunity

Jan 20
If EPS Growth Is Important To You, Cross Country Healthcare (NASDAQ:CCRN) Presents An Opportunity

Cross Country Healthcare (NASDAQ:CCRN) Has A Rock Solid Balance Sheet

Jan 05
Cross Country Healthcare (NASDAQ:CCRN) Has A Rock Solid Balance Sheet

Is Now The Time To Look At Buying Cross Country Healthcare, Inc. (NASDAQ:CCRN)?

Oct 29
Is Now The Time To Look At Buying Cross Country Healthcare, Inc. (NASDAQ:CCRN)?

Investors Shouldn't Overlook Cross Country Healthcare's (NASDAQ:CCRN) Impressive Returns On Capital

Oct 14
Investors Shouldn't Overlook Cross Country Healthcare's (NASDAQ:CCRN) Impressive Returns On Capital

Paring My Cross Country Healthcare Gains

Sep 29

Should You Be Adding Cross Country Healthcare (NASDAQ:CCRN) To Your Watchlist Today?

Sep 26
Should You Be Adding Cross Country Healthcare (NASDAQ:CCRN) To Your Watchlist Today?

Cross Country Healthcare to acquire assets of Mint Medical Physician Staffing, LP and Lotus Medical Staffing LLC

Sep 14

Cross Country Healthcare (NASDAQ:CCRN) Has A Pretty Healthy Balance Sheet

Aug 21
Cross Country Healthcare (NASDAQ:CCRN) Has A Pretty Healthy Balance Sheet

Cross Country Healthcare rises postmarket on $100M stock buyback program

Aug 16

Cross Country Healthcare Q2 Non-GAAP EPS, revenue beats, Q3 guidance provided

Aug 03

Earnings and Revenue Growth Forecasts

NasdaqGS:CCRN - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20261,29423N/AN/A4
12/31/20251,2651942498
12/31/20241,341-7971058
9/30/20241,448-299108N/A
6/30/20241,5758159171N/A
3/31/20241,77646195208N/A
12/31/20232,02073235248N/A
9/30/20232,234102228241N/A
6/30/20232,428124298311N/A
3/31/20232,641156200210N/A
12/31/20222,807188125134N/A
9/30/20222,8192274756N/A
6/30/20222,558216-95-87N/A
3/31/20222,136175-98-90N/A
12/31/20211,677132-93-86N/A
9/30/20211,25259-16-10N/A
6/30/20211,07134-21-16N/A
3/31/20219569-20-15N/A
12/31/2020836-132327N/A
9/30/2020836-191520N/A
6/30/2020851-211014N/A
3/31/2020837-58710N/A
12/31/2019822-5836N/A
9/30/2019808-76710N/A
6/30/2019800-742428N/A
3/31/2019801-201621N/A
12/31/2018816-171621N/A
9/30/2018835313439N/A
6/30/201886338N/A38N/A
3/31/201886841N/A57N/A
12/31/201786538N/A46N/A
9/30/20178682N/A27N/A
6/30/20178549N/A43N/A
3/31/2017845-13N/A29N/A
12/31/20168348N/A30N/A
9/30/201680410N/A32N/A
6/30/20167851N/A25N/A
3/31/201677821N/A21N/A
12/31/20157674N/A18N/A
9/30/2015762-10N/A18N/A
6/30/2015756-22N/A7N/A
3/31/2015686-28N/A5N/A
12/31/2014618-32N/A-4N/A
9/30/2014539-64N/A-6N/A
6/30/2014458-55N/A-1N/A
3/31/2014446-54N/A1N/A
12/31/2013438-54N/A9N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CCRN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).

Earnings vs Market: CCRN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CCRN is expected to become profitable in the next 3 years.

Revenue vs Market: CCRN's revenue is expected to decline over the next 3 years (-5.3% per year).

High Growth Revenue: CCRN's revenue is forecast to decline over the next 3 years (-5.3% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CCRN's Return on Equity is forecast to be low in 3 years time (4.2%).


Discover growth companies